Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR/HDAC targeted therapy

Bladder cancer (BC) is one of the most prevalent malignancies worldwide and FGFR3 alterations are particularly common in BC. Despite approval of erdafitinib, durable responses for FGFR inhibitors are still uncommon and most patients relapse to metastatic disease. Given the necessity to discover more...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zechen, Muthusamy, Viswanathan, Petrylak, Daniel P., Anderson, Karen S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362036/
https://www.ncbi.nlm.nih.gov/pubmed/37479885
http://dx.doi.org/10.1038/s41698-023-00417-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362036/
https://www.ncbi.nlm.nih.gov/pubmed/37479885
http://dx.doi.org/10.1038/s41698-023-00417-5

Ejemplares similares